Great news that Synapix Bio have secured £13.2m to fund clinical trials for H-ABC/Tubb4a!habcfoundationukMay 10, 20231 min readOxford biotech firm secures £13.2m to develop first treatment for rare, incurable, deadly disease. (synaptixbio.com)
In a major article for Drug Discovery World, Dan Williams discussed the opportunities for ASO-based therapies
Addressing the Funding Crisis for Special Needs Education in the UKBeing a parent of a child suffering from Hypomyelination with Atrophy of the Basal Ganglia and Cerebellum (H-ABC), a condition caused by...
Comentarios